Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882


Real-time Quote. Real-time CHI-X - 12/16 09:12:42 am
1775.3 GBp   +2.92%
12/13UK Plc shares hail Johnson's storming election victory
12/12UK'S WINTER ELECTION : What's in it for markets?
12/12UK'S WINTER ELECTION : What's in it for markets?
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Nestle aims to shed skin unit to focus on food, nutrition

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20/2018 | 07:45am EST
FILE PHOTO: The Nestle logo is seen during the opening of the 151st Annual General Meeting of Nestle in Lausanne

LONDON/ZURICH (Reuters) - Nestle put its skin health unit up for sale on Thursday, as the maker of Nescafe and Perrier water ditches underperforming businesses and fends off criticism from an activist investor demanding an overhaul.

Nestle said it was exploring strategic options for the unit, saying "the future growth opportunities of Nestle Skin Health lie increasingly outside the group's strategic scope" and did not fit in with a sharper focus on food, drinks and nutritional health.

Nestle agreed this week to sell its Gerber Life Insurance business for $1.55 billion, while sources told Reuters it was also bidding for GlaxoSmithKline Horlicks drink.

The skin health unit makes Cetaphil and Proactiv skin care brands, Restylane wrinkle fillers and prescription dermatology treatments. It had sales of 2.7 billion Swiss francs ($2.8 billion) last year, accounting for about 3 percent of Nestle's total.

Vontobel analyst Jean-Philippe Bertschy estimated the business was worth 6 billion to 6.5 billion francs, excluding financial debt, provisions and deferred taxes. He said it could fetch between 6 billion and 8 billion francs in a sale. Another analyst put the sale value at about 7 billion francs.

Nestle Skin Health was formed in 2014 when Nestle bought L'Oreal's stake in their Galderma dermatology venture.

Jefferies analyst Martin Deboo said the most likely exit options were a leveraged buyout or a sale to L'Oreal, if the French cosmetics firm followed Nestle in making a strategic U-turn.

L'Oreal, in which Nestle is a shareholder, declined to comment.


Nestle, the world's largest packaged food company, is under pressure from Third Point, a hedge fund run by investor Daniel Loeb, to take bold moves to improve returns.

Chief Executive Mark Schneider, the first externally hired CEO in nearly a century, has addressed several of Third Point's demands, including setting a margin target and speeding up acquisitions and divestitures.

The one demand he has not addressed is the sale of Nestle's 23 percent stake in L'Oreal, worth nearly 26 billion euros.

Baader Helvea analyst Andreas von Arx said the plan to exit skin health could reignite talk about the stake since that also lay outside the vision Nestle outlined on Thursday.

"Sharpening our strategic focus on Nestle's core food, beverage and nutritional health products offers the best opportunity for long-term profitable growth and is fully in line with the pursuit of our company's purpose," said Paul Bulcke, Nestle's chairman and former CEO.


When Bulcke ran Nestle, skin treatments were a major part of a push into higher growth and more profitable health products taken to counter a slowdown in its traditional food businesses.

But the unit has performed poorly, incurring one-off costs including inventory writedowns and a significant goodwill impairment this year. Last year, Nestle started restructuring the business, cutting jobs and closing a factory.

Divesting the business represents a symbolic break with the decisions of Schneider's predecessors, Jefferies' Deboo said.

"This in turn suggests that Schneider is being given full latitude to act in the interests of shareholder value, unbounded by the decisions of the past," he said.

Exiting skin health is something many analysts and investors had asked for, Baader Helvea's von Arx said, adding that it put Nestle "fully on track" to deliver on Schneider's promise last September to swap out as much as 10 percent of its portfolio.

Nestle has also sold its U.S. confectionery unit, and has done several deals in coffee, involving Starbucks and Blue Bottle.

The skin health review is due to be completed by mid-2019.

At the same time, Nestle said it remained committed to its health science unit, which sells medical nutritional products and bulked up with the purchase of a vitamin business this year.

Nestle shares were up nearly 1 percent at 1049 GMT.

(Additional reporting by Sarah White in Paris; Editing by Sherry Jacob-Phillips and Edmund Blair)

By Martinne Geller and John Revill

Stocks mentioned in the article
ChangeLast1st jan.
FORBO HOLDING AG 0.73% 1660 Delayed Quote.18.97%
GLAXOSMITHKLINE 2.50% 1767.8 Delayed Quote.15.68%
L'ORÉAL 1.60% 260.5 Real-time Quote.27.39%
NESTLÉ S.A. 1.34% 104.2 Delayed Quote.29.00%
STARBUCKS CORPORATION 0.52% 88.67 Delayed Quote.37.69%
share with twitter share with LinkedIn share with facebook
share via e-mail
12/13UK Plc shares hail Johnson's storming election victory
12/12UK'S WINTER ELECTION : What's in it for markets?
12/12UK'S WINTER ELECTION : What's in it for markets?
12/10SPRINGWORKS THERAPEUTICS : Researchers Present Preclinical Data Showing Synergis..
12/10Sanofi shares rally on new margin goals, narrower drug focus
12/06GLAXOSMITHKLINE : ViiV Healthcare reaffirms future commitment to industry leadin..
12/05UK bribery investigation adds to Glencore's legal headaches
12/03Corporate Tax Chiefs Voice Concerns About Global Minimum Tax Proposal
11/26GLAXOSMITHKLINE : Block listing Interim Review
11/22GLAXOSMITHKLINE : ViiV Healthcare announces exclusive licensing agreement with t..
More news
Financials (GBP)
Sales 2019 33 461 M
EBIT 2019 9 126 M
Net income 2019 4 300 M
Debt 2019 25 069 M
Yield 2019 4,64%
P/E ratio 2019 19,2x
P/E ratio 2020 16,0x
EV / Sales2019 3,30x
EV / Sales2020 3,07x
Capitalization 85 378 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 1 824,50  GBp
Last Close Price 1 725,00  GBp
Spread / Highest target 27,5%
Spread / Average Target 5,77%
Spread / Lowest Target -12,5%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.55%372 094
ROCHE HOLDING AG23.48%261 287
MERCK AND COMPANY16.73%227 076
PFIZER-12.19%212 123
NOVARTIS22.77%210 097